MorphoSys
-
Novartis’s MorphoSys Acquisition Comes With Cancer Drugs & Antitrust Questions
Novartis’s €2.7B acquisition of MorphoSys brings two cancer drug candidates, one of which would give the pharmaceutical giant a way to stand apart from other myelofibrosis treatments. In a separate deal, MorphoSys sold to Incyte its rights to a partnered blood cancer drug.
-
‘Challenging Market’ Leads MorphoSys to Cut Preclinical R&D, Turn Focus to Cancer
MorphoSys’s emphasis on its clinical-stage cancer programs puts the spotlight on a myelofibrosis drug candidate from its 2021 acquisition of Constellation Pharmaceuticals. That small molecule could compete against drug candidates from GSK and Merck.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
MorphoSys cuts R&D from Constellation deal to focus on clinical-stage cancer drugs
MorphoSys is cutting the drug discovery and R&D work of Constellation Pharmaceuticals, a company it acquired last year in a $1.7 billion deal. This consolidation of research operations will result in a non-cash impairment charge on Constellation’s goodwill.
-
BioMarin stands tall with first approved drug for rare disease that causes dwarfism
The European Commission has approved a BioMarin Pharmaceutical drug that treats achondroplasia, a rare genetic disorder that slows bone growth and is the most common cause of dwarfism. The commission also granted conditional approval to a cancer drug from partners Incyte and MorphoSys.
-
MorphoSys to buy Constellation Pharma in a $1.7B bet on epigenetic cancer drugs
MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the acquisition with cash from a separate $2 billion deal with drug royalty acquirer Royalty Pharma.
-
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
The FDA approved Monjuvi for second-line diffuse large B-cell lymphoma. Though the drug has the same antigen target as approved CAR-T cell therapies, it is designed for patients unable to tolerate such intensive treatments.
-
Incyte pays MorphoSys $750M upfront in lymphoma drug partnership
The deal, worth up to $2B in milestones and other other payments, involves the monoclonal antibody tafasitamab, for which MorphoSys recently submitted an FDA approval application.
-
MorphoSys files for approval of drug for hard-to-treat lymphoma patients
The German biotech company said Monday it had applied for approval of tafasitamab in diffuse large B-cell lymphoma, which targets the same antigen as CAR-T, but would be for a population unable to tolerate the cell therapies.
-
MorphoSys builds out U.S. infrastructure for anticipated launch of lymphoma drug
The German drugmaker plans to submit its data package for FDA approval by the end of the year, with potential approval next year. The package will include a synthetic control arm comprising real-world data.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
MorphoSys posts positive data for lymphoma drug, but will it compete with CAR-Ts?
A spokesperson for the company noted that patients in the Phase II L-MIND trial of the CD19-targeting drug tafasitamab would be too old and frail to be candidates for CAR-T therapies.